Skip to content
    KYMR
    Earnings call· Dec 2025(Q4 FY25)

    Kymera Therapeutics Q4 FY25 earnings call KYMR

    Feb 26, 2026 Source

    Executive summary

    Kymera Therapeutics Q4 FY25 — Strong Pipeline Progress and Extended Cash Runway

    Kymera Therapeutics concluded a pivotal Q4 FY25, marked by significant clinical advancements and a strengthened financial position. The company initiated Phase IIb trials for its lead STAT6 degrader, KT-621, in atopic dermatitis and asthma, building on strong Phase I data. Additionally, its first-in-class IRF5 degrader, KT-579, entered Phase I, expanding the immunology pipeline. Strategic collaborations and a substantial cash balance extending into 2029 underpin ambitious development plans for 2026 and beyond.

    Highlights

    5

    • KT-621 Phase I/Ib results demonstrated robust STAT6 degradation, excellent safety, and encouraging efficacy, leading to Phase IIb studies in AD and asthma.

    • Initiated dosing in Phase I healthy volunteer study for first-in-class IRF5 degrader, KT-579, after IND clearance.

    • Raised almost $1 billion in 2025, extending cash balance to $1.6 billion into 2029, funding key clinical programs.

    • New partnership with Gilead for CDK2 molecular glue program, with potential milestones up to $750 million.

    • Sanofi advancing KT-485 (IRAK4 degrader) to Phase I, with potential milestones up to nearly $1 billion.

    Concerns

    2

    • Placebo effect in clinical trials

    • Oral drug adherence in clinical trials

    Guidance & targets

    9
    CategoryTargetConfidence
    KT-621 AD study enrollment completion
    End of 2026
    medium materiality
    High
    KT-621 AD study top-line results
    Mid-2027
    high materiality
    High
    KT-621 asthma study data
    Late 2027
    high materiality
    High
    KT-579 Phase I healthy volunteer study completion and data
    Later this year
    medium materiality
    High
    KT-579 patient proof-of-concept study
    Soon after Phase I data
    medium materiality
    Medium
    Sanofi KT-485 Phase I trial initiation
    This year
    low materiality
    High
    CDK2 program advancement with Gilead
    Further development
    low materiality
    Medium
    New program announcement
    At least one new program annually, targeting H2 2026
    medium materiality
    High
    Cash runway
    Into 2029
    high materiality
    High

    Operational metrics

    23
    Collaboration revenue
    $2.9M
    Q4 FY25

    Attributable to the Gilead partnership.

    Gilead upfront payment
    $40M
    Last year

    Received upon signing the licensing and option agreement.

    Gilead total milestone payments potential
    $750M
    Total

    Eligible under the licensing and option agreement.

    Gilead option payment (CDK2 program)
    $45M
    Upon option exercise

    Payable if Gilead exercises its option on the CDK2 program at the declaration of a mutually agreed upon development candidate.

    Sanofi total milestone payments potential
    Nearly $1B
    Total

    Potential under the Sanofi agreement for KT-485.

    R&D expense
    $83.8M
    Q4 FY25

    Total R&D expense for the quarter.

    Noncash stock-based compensation (R&D)
    $7.6M
    Q4 FY25

    Portion of R&D expense.

    Adjusted cash R&D spend
    $76.2M16% increase from Q3 FY25
    Q4 FY25

    Excludes noncash stock-based compensation.

    G&A expense
    $16.9M
    Q4 FY25

    Total G&A expense for the quarter.

    Noncash stock-based compensation (G&A)
    $6.9M
    Q4 FY25

    Portion of G&A expense.

    Adjusted cash G&A spend
    $10M1% increase from Q3 FY25
    Q4 FY25

    Excludes noncash stock-based compensation.

    Cash balance
    $1.6B
    End of December 2025

    Year-end cash balance.

    Diagnosed Type 2 patients
    140M
    Current

    Estimated total diagnosed Type 2 patients.

    Moderate to severe Type 2 patients
    50M
    Current

    Estimated patients in the moderate to severe category.

    Patients treated with advanced systemic therapies
    2M
    Current

    Estimated patients currently receiving advanced systemic therapies for Type 2 diseases.

    Type 2 market value
    $20B
    Annual

    Current annual market value for advanced systemic therapies in Type 2 diseases.

    Dupilumab share of systemic therapy use
    >75%
    Current

    Represents the majority of systemic therapy use.

    Psoriasis market growth
    Fivefold
    Past decade

    Cited as a comparable example of market expansion due to new drugs and oral therapies.

    KT-621 Phase IIb AD study enrollment
    ~200
    Current

    Target enrollment for the BROADEN2 trial.

    KT-621 Phase IIb asthma study enrollment
    ~264
    Current

    Target enrollment for the BREADTH trial.

    Total patients in KT-621 Phase IIb studies
    Close to 500
    Next year

    Expected total patients across both AD and asthma Phase IIb studies.

    IRF5 functional inhibition target
    50% to 80%
    Target

    Expected reduction in biomarkers across TLR7, 8, and 9 pathways in ex vivo stimulation assays.

    IRF5 knockdown target
    90% or greater
    Target

    Defined as robust degradation of IRF5 in blood in the Phase I healthy volunteer study.

    Deals & partnerships

    2
    SanofiCollaboration for advancing KT-485, an oral IRAK4 degrader, into Phase I testing.Potential to realize nearly $1 billion in total milestones

    Existing collaboration under which Sanofi is advancing KT-485.

    GileadNew partnership around Kymera's first-in-class CDK2 molecular glue program.Upfront payment of $40 million; eligible for up to $750 million in total milestone payments.

    Signed last year, includes a licensing and option agreement.

    Risks & headwinds

    2
    Placebo effect in clinical trialsOngoing in Phase IIb studies

    N/A

    Mitigation: Careful eligibility criteria, oversight to ensure patients meet criteria for moderate to severe disease, trained and certified investigators, global site selection (majority ex-US) where access to drugs like dupilumab is diminished, attracting more severe patients.

    Oral drug adherence in clinical trialsOngoing in Phase IIb studies

    Injectable biologics ensure 100% adherence, but oral drugs offer patients freedom.

    Mitigation: Measures to understand patient adherence well; protein degraders like KT-621 offer protection against missed doses (no loss of pathway degradation from one missed dose).

    What to watch in Q1 FY26

    5

    KT-579 Phase I healthy volunteer data

    Later this year (2026)
    CurrentDosing initiated
    TargetData shared

    Why it matters

    Will provide first-in-human data on IRF5 degradation and functional impact, de-risking subsequent patient studies.

    We expect to complete the recently started Phase I healthy volunteer study and share the data later this year.

    Q&A highlights

    7

    What is Kymera's vision for the evolving AD treatment landscape, and what can be learned from the IRF5 healthy volunteer study beyond safety and target engagement?

    Nello stated the AD market is early with significant unmet need (40-50M moderate-to-severe patients, only 2M treated), requiring new therapies. KT-621 targets a well-validated pathway (IL-4/13) with intracellular action, offering de-risking. Jared explained the IRF5 healthy volunteer study will show 90%+ knockdown and functional inhibition (50-80% reduction) of TLR-stimulated pathways (Type 1 interferons, pro-inflammatory cytokines, B cell autoantibodies) via ex vivo assays, which de-risks subsequent patient studies.

    “And to be able to show an impact across those 3 pathways on ex vivo stim, we believe, significantly derisk our probability of success in subsequent patient studies, including the lupus studies.”

    asked by Marc Frahm · answered by Jared Gollob

    2 min read6 chapters

    Detailed Narrative

    01

    2025 Accomplishments & 10th Anniversary

    Kymera Therapeutics celebrated its 10th anniversary in May 2016, highlighting 2025 as a breakout year with significant progress across its pipeline. The company has built robust capabilities and a team to develop breakthrough immunology medicines, executing on its strategy over the past decade. This foundational work sets the stage for ambitious plans in 2026 and beyond.

    02

    KT-621 Clinical Progress

    KT-621, the first-in-class STAT6 degrader, showed outstanding results from both its Phase I healthy volunteer study and Phase Ib study in AD patients. These studies demonstrated robust STAT6 degradation with excellent safety and tolerability, alongside encouraging efficacy endpoints. Building on this, Kymera launched Phase IIb studies in atopic dermatitis (BROADEN2) and asthma (BREADTH), aiming to deliver biologics-like efficacy with oral daily dosing convenience.

    03

    KT-579 Advancement

    Kymera advanced its first-in-class IRF5 program, KT-579, completing IND-enabling studies in 2025. Following IND clearance from the FDA, the company recently initiated dosing in a Phase I healthy volunteer study. This program is supported by a compelling preclinical profile and validating human genetics, positioning it as an exciting new opportunity for complex autoimmune diseases.

    04

    Collaborations and Financial Strength

    The company strengthened its financial position and expanded its pipeline through strategic collaborations. Existing partnerships with Sanofi for IRAK4 (KT-485) are progressing, with Sanofi expected to initiate Phase I testing this year. A new partnership was signed with Gilead for the CDK2 molecular glue program. Kymera raised almost $1 billion in 2025, ending the year with a $1.6 billion cash balance, extending its runway into 2029 to fund broad development plans.

    05

    Market Opportunity for STAT6 Program

    Management emphasized the unprecedented🌐 market opportunity for the STAT6 program, noting that out of approximately 140 million diagnosed Type 2 patients in major markets, only an estimated 2 million are treated with advanced systemic therapies. The current annual market value is around $20 billion, predominantly driven by dupilumab. Kymera believes KT-621, as a convenient oral therapy with biologics-like efficacy and safety, can significantly expand this market by addressing unmet needs and offering an alternative to injectables.

    06

    IRF5 Mechanism and Potential

    KT-579 is designed to selectively degrade IRF5, a genetically validated transcription factor that acts as a central amplifier of immune responses. This approach aims to modulate interconnected inflammatory pathways (Type 1 interferons, pro-inflammatory cytokines, B cell-derived autoantibodies) simultaneously. The goal is to achieve more effective and durable disease control in autoimmune diseases like lupus, IBD, and RA, rebalancing the immune system without broad immunosuppression.

    AI-generated summary of the company’s earnings call. Not investment advice.